...
首页> 外文期刊>International journal of hyperthermia: The official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group >Clinical pilot studies on pre-operative hyperthermic tumour ablation for advanced breast carcinoma using an 8 MHz radiofrequency heating device.
【24h】

Clinical pilot studies on pre-operative hyperthermic tumour ablation for advanced breast carcinoma using an 8 MHz radiofrequency heating device.

机译:使用8 MHz射频加热设备对晚期乳腺癌进行术前高温热消融的临床试验研究。

获取原文
获取原文并翻译 | 示例
           

摘要

The multimodality treatment approach for advanced breast cancer provides survival advantages with decreased locoregional and distant recurrences, but these intensive anti-tumour treatments cause severe myelosuppression. Thus, in this study, the usefulness of pre-operative anti-tumour treatment without myelosuppression was investigated. Nine patients with advanced breast carcinoma underwent pre-operative hyperthermic tumour ablation (HTA) using an 8 MHz radiofrequency (RF) heating device (Thermotron RF-8) combined with a grounded needle electrode. The patients had a mean age of 58.3+/-13.9 years and included four patients with stage IIIA, two with stage IIIB and three with stage IV cancer. The target temperature was over 50 degrees C. They tolerated pre-operative HTA therapy well with no early or late complications. The initial mean tumour size was 122.1+/-71.5 cm(3) and the post-HTA tumour size was 82.2+/-63.4 cm(3); the reduction rate was significant (p = 0.000 293). After the pre-operative HTA, all patients underwent surgery with Level III nodal extirpation. Post-operatively, no locoregional recurrence was observed. Microscopic examination of the primary focus showed complete coagulation necrosis expanding for a diameter of 3.5-5.0 cm. Taken together, the pre-operative HTA was a safe, well-tolerated and effective treatment, achieving tumour reduction as well as complete coagulation necrosis that resulted in a large volume of destruction in breast cancer tissue.
机译:晚期乳腺癌的多模式治疗方法具有生存优势,局部区域和远处复发率降低,但是这些密集的抗肿瘤治疗会导致严重的骨髓抑制。因此,在这项研究中,研究了没有骨髓抑制的术前抗肿瘤治疗的有用性。九名晚期乳腺癌患者使用8 MHz射频(RF)加热设备(Thermotron RF-8)结合接地的针电极进行了术前高温肿瘤消融(HTA)。这些患者的平均年龄为58.3 +/- 13.9岁,包括四名IIIA期患者,两名IIIB期患者和三名IV期癌症患者。目标温度超过50摄氏度。他们对术前HTA治疗耐受良好,没有早期或晚期并发症。初始平均肿瘤大小为122.1 +/- 71.5 cm(3),HTA后肿瘤大小为82.2 +/- 63.4 cm(3);减少率显着(p = 0.000 293)。术前HTA后,所有患者均接受了III级结节摘除术。术后未观察到局部复发。显微镜检查的主要病灶显示完全凝结坏死扩大为直径3.5-5.0厘米。综上所述,术前HTA是一种安全,耐受良好且有效的治疗方法,可减少肿瘤以及完全凝固坏死,从而导致乳腺癌组织大量破坏。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号